Analyst Joanna Gajuk from Bank of America Securities reiterated a Buy rating on BrightSpring Health Services, Inc. and increased the price target to $38.00 from $31.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Joanna Gajuk’s rating is based on BrightSpring Health Services, Inc.’s strong performance and future growth prospects. The company has increased its revenue guidance and maintained its EBITDA outlook, showcasing confidence in its ability to achieve double-digit growth, particularly driven by its Oncology Pharmacy and Infusion business. The company’s leverage is also improving, with expectations to reduce it significantly by mid-2026, aided by strategic asset sales and acquisitions.
Moreover, BrightSpring has demonstrated robust growth in its pharmacy segment, with a notable increase in gross profit per script due to generic conversions and an impressive rise in Infusion and Specialty revenues. Despite some challenges in the Home/Community Pharmacy segment, the overall growth in Specialty scripts and other healthcare services like Hospice and Home Health Care supports the positive outlook. These factors contribute to the raised price objective and reinforce the Buy rating.
In another report released today, TD Cowen also reiterated a Buy rating on the stock with a $42.00 price target.